DEXLIFE

Mechanisms of prevention of type 2 diabetes by lifestyle intervention in subjects with pre-diabetes or at high-risk for progression

Coordinatore	Steno Diabetes Center A/S    more  Organization address address: Niels Steensens Vej 2 city: Gentofte postcode: 2820 contact info Titolo: Prof. Nome: John Cognome: Nolan Email: send email Telefono: +45 3968 0800
Nazionalità Coordinatore	Denmark [DK]
Sito del progetto	http://dexlife.eu/
Totale costo	7˙912˙027 €
EC contributo	5˙486˙631 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2011-two-stage
Funding Scheme	CP-FP
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-01-01   -   2015-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	Steno Diabetes Center A/S  Organization address address: Niels Steensens Vej 2 city: Gentofte postcode: 2820 contact info Titolo: Prof. Nome: John Cognome: Nolan Email: send email Telefono: +45 3968 0800	DK (Gentofte)	coordinator	942˙495.57
2	FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA)  Organization address address: CARRER BALDIRI REIXAC 10-12 PARC SCIENTIFIC DE BARCELONA city: BARCELONA postcode: 8028 contact info Titolo: Ms. Nome: Adriana Cognome: Grosu Email: send email Telefono: +34 93 4020450	ES (BARCELONA)	participant	1˙003˙638.48
3	DUBLIN CITY UNIVERSITY  Organization address address: Glasnevin city: DUBLIN postcode: 9 contact info Titolo: Dr. Nome: Donal Cognome: O'gorman Email: send email Telefono: +353 17008060	IE (DUBLIN)	participant	905˙443.60
4	FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE  Organization address address: AVENIDA GRAN VIA HOSPITALET 199-203 city: L'HOSPITALET DE LLOBREGAT postcode: 8908 contact info Titolo: Ms. Nome: Laia Cognome: Lagunas Email: send email Telefono: 34932607109 Fax: 34932607224	ES (L'HOSPITALET DE LLOBREGAT)	participant	560˙800.00
5	METABOLON INC CORPORATION  Organization address address: RESEARCH TRIANGLE PARK city: DURHAM NC postcode: 27709 contact info Titolo: Dr. Nome: Walter Cognome: Gall Email: send email Telefono: +1 9196272518 Fax: +1 9195721721	US (DURHAM NC)	participant	554˙395.88
6	TEKNOLOGIAN TUTKIMUSKESKUS VTT  Organization address address: TEKNIIKANTIE 4 A city: ESPOO postcode: 02044 VTT contact info Titolo: Dr. Nome: Jing Cognome: Tang Email: send email Telefono: 358404000000 Fax: 358207000000	FI (ESPOO)	participant	431˙364.67
7	VOLUNTARY HEALTH INSURANCE BOARD  Organization address address: LOWER ABBEY STREET 20 VHI HOUSE city: DUBLIN postcode: 1 contact info Titolo: Dr. Nome: Bernadette Cognome: Carr Email: send email Telefono: +353 1 614 7302 Fax: +353 874 8390	IE (DUBLIN)	participant	374˙518.80
8	UNIVERSITY OF NEWCASTLE UPON TYNE  Organization address address: Kensington Terrace 6 city: NEWCASTLE UPON TYNE postcode: NE1 7RU contact info Titolo: Dr. Nome: Amanda Cognome: Gregory Email: send email Telefono: +44 191 2824514 Fax: +44 191 2824524	UK (NEWCASTLE UPON TYNE)	participant	282˙770.00
9	Nome Ente NON disponibile  Organization address address: YLIOPISTONRANTA 1 E city: Kuopio postcode: 70211 contact info Titolo: Ms. Nome: Tiina Cognome: Reinikainen Email: send email Telefono: +358 40 512 1200	FI (Kuopio)	participant	232˙480.00
10	PINTAIL LTD  Organization address address: SPRINGHILL AVENUE 77 city: BLACKROCK contact info Titolo: Mr. Nome: Ciaran Cognome: Clissmann Email: send email Telefono: +353 1 2899529	IE (BLACKROCK)	participant	198˙724.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Type 2 diabetes (T2DM) is preventable by sustained changes in diet and physical exercise. Despite this, modern societies are already approaching 10% population prevalence of diabetes, and another 15% with pre-diabetes. The costs of T2DM are huge, approaching 10% of all health costs. Prevention of diabetes is a priority for national healthcare agencies and for the health insurance industry. Investment in prevention and lifestyle programmes requires a solid evidence-base for targeting and customising these interventions in a cost-effective manner. Translation of the findings from T2DM prevention studies to the benefit of general public health has not yet been possible. DEXLIFE will identify novel diagnostic and predictive biomarkers (i) to detect the progression toward diabetes in high risk individuals and (ii) that are responsive to lifestyle interventions known to be effective in diabetes prevention. New biomarkers alone will be insufficient to alter the course of diabetes progression. We bring a strong translational focus to this proposal, by setting the main intervention in the real-life context of a major health insurance system. The accumulated phenotyping repertoire from an extensive panel of –omic analyses will be refined and modelled into a new diagnostic panel for the allocation of high risk subjects to individualised preventive regimens. Our multi-disciplinary team has a strong track record in clinical diabetes and metabolism. Several unique clinical cohorts will provide the basis for a series of clinical, physiological and mechanistic investigations, which will identify, monitor and analyse the impact of biomarkers over time. An exercise and dietary intervention study will be included in two specific cohorts, enabling us to assess the impact of such interventions on plasma biomarkers and functional tissue-based markers. Project clinical and industry partners will support the translation of our findings into clinical practice.'